z-logo
open-access-imgOpen Access
Clinical and pathogenetic role of peroxisome proliferator-activated receptor alpha in atherogenesis
Author(s) -
Е. И. Красильникова,
Anna Kostareva,
Д. Саха,
S Hosseinpour Sakha,
Elena G. Sergeeva,
О. А. Беркович,
Т. В. Антонова,
А. В. Горбач,
М. А. Романова,
Ж. И. Ионова,
А. А. Быстрова,
Е. В. Шляхто
Publication year - 2012
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2012-18-1-18-24
Subject(s) - chylomicron , peroxisome , receptor , peroxisome proliferator activated receptor , endocrinology , lipoprotein lipase , medicine , peroxisome proliferator activated receptor alpha , triglyceride , inflammation , chemistry , alpha (finance) , lipoprotein , cholesterol , biology , adipose tissue , nuclear receptor , biochemistry , very low density lipoprotein , transcription factor , construct validity , nursing , gene , patient satisfaction
Peroxisome proliferator receptors alpha (PPAR-α) and their role in atherogenesis has a great practical significance, since there are drugs that can enhance the activity of these receptors. Activation of PPAR-α by fibrates is known to lead to both significant reduction of serum triglyceride levels by activation of lipoprotein lipase, and to the increase of synthesis of the main apolipoproteins within high-density lipoproteins (HDL), contributing to the reverse transport of cholesterol from chylomicrons and very low-density lipoproteins to the liver. Besides, PPAR-α increase the capture of HDL by liver. PPAR-α also participate in the regulation of inflammation, expression of adhesive molecules, production of chemotactic factors, as well as inhibit the proliferation of smooth muscle cells and activity of fibroblasts. These data suggest that PPAR-α are directly involved in the processes of atherogenesis, and their activation may contribute to the regression of atherosclerotic plaque and significant reduction of cardiometabolic risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here